There were 938 press releases posted in the last 24 hours and 193,768 in the last 365 days.

Balanced Biotech & Colorado State University enter into licensing agreement for point-of-care COVID-19 antigen test.

Image Caption: The Balanced Biotech Rapid On-the-Spot COVID Test (ROCT) developed collaboration with three Colorado State University professors is designed for self-administered nasal swab samples for pain-free, non-invasive sample collection.

Balanced Biotech and Colorado State University enter into licensing agreement for a cutting-edge novel electronic point-of-care COVID-19 antigen test.

COLUMBUS, OH, UNITED STATES, November 16, 2020 /EINPresswire.com/ -- NEWS RELEASE
FOR IMMEDIATE RELEASE
Nov. 11, 2020
Contacts: Sarah Hibbs-Shipp, CSURF - CSU Ventures; Krista Meyer PhD, Balanced Biotech


FORT COLLINS, Colo. - Balanced Biotech (www.balancedbiotech.com and www.balanceddiagnostics.com) has licensed a novel, rapid COVID-19 antigen test technology developed in collaboration with three professors and their students at Colorado State University. The licensing agreement was facilitated by the Colorado State University Research Foundation, which houses CSU Ventures – the technology transfer office that manages intellectual property for the CSU System.

This unique test relies on a simple yet robust sensing method similar to what is used in handheld glucometers, providing a sensitive, specific, and quantitative way to detect active COVID-19 infection. The Rapid On-the-Spot COVID Test (ROCT) is initially being designed for use with self-administered nasal swab samples for pain-free, non-invasive sample collection.

This fully self-contained device has all the necessary electronics built into it, eliminating the need for a test reader. As a result, the user needs only to download the device app to their phone; the app is then used to scan the device to interpret the results. The app will indicate a positive or negative result, and also indicate if a retest should be done in cases of an uncertain result.

Early results with this revolutionary technology show that the ROCT is substantially more sensitive at detecting active COVID-19 infection than existing point-of-care tests on the market. It is more portable and provides a simple, non-invasive test for the end user to perform and obtain accurate results. Pre-clinical and early stage clinical trials are currently underway to further evaluate the technology for broad distribution.

The ROCT platform will offer a true end-to-end solution for rapid COVID-19 testing that will not only offer results in minutes but also provide real-time reporting of those results at the individual, employer, school, state and national levels. This gives users the ability to contact trace in real time and potentially get ahead of the virus by putting the appropriate actions in place.

Balanced Biotech Inc. located in Columbus OH, is a U.S. based life science company. Our research is focused on advancing how healthcare providers diagnose and treat their patients by developing cutting-edge Point of Care diagnostics and leveraging proprietary carriers of active substances as a transport system for oncological, anti-inflammatory, analgesic drugs and many more, increasing their targeted effects by up to 10 times, reducing the drug dose by 10 times and radically minimizing the side effects of therapy.

This is the second COVID-19 screening technology to be developed by the interdisciplinary group of CSU researchers, which includes Charles Henry, Department of Chemistry, College of Natural Sciences; David Dandy, Department of Chemical & Biological Engineering, Walter Scott, Jr. College of Engineering; and Brian Geiss, Department of Microbiology, Immunology, and Pathology, College of Veterinary Medicine and Biomedical Sciences. All three professors have extensive innovation experience and have successfully developed and licensed multiple technologies across several disciplines.

Raymond Kalmar
Balanced Biotech Inc
ray@balancedbiotech.com